Rydex Biotechnology Fund Class A RYBOX

Morningstar Medalist Rating
  • NAV / 1-Day Return $79.42  /  +2.10 %
  • Fund Size $157.6M
  • Adjusted Expense Ratio 1.630%
  • Net Expense Ratio 1.630%
  • Fee Level: Distribution High
  • Share Class Type Front Load
  • Morningstar Category Health
  • Equity Style Box (Funds) Mid Blend
  • Minimum Initial Investment $2,500
  • Investment Status Open
  • TTM Yield 0.00%
  • Turnover Ratio 75%

Morningstar’s Analysis RYBOX

Will RYBOX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Rydex Biotechnology A holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYBOX

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 40.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

7.88 10M
Healthcare

Amgen Inc

5.67 8M
Healthcare

Gilead Sciences Inc

4.93 7M
Healthcare

Vertex Pharmaceuticals Inc

4.48 6M
Healthcare

Moderna Inc

4.08 5M
Healthcare

Regeneron Pharmaceuticals Inc

3.56 5M
Healthcare

BeOne Medicines Ltd ADR

2.59 3M
Healthcare

Revolution Medicines Inc Ordinary Shares

2.58 3M
Healthcare

Natera Inc

2.38 3M
Healthcare

Illumina Inc

2.23 3M
Healthcare

Sponsor Center